Chemours (NYSE:CC) Upgraded at Zacks Research

Zacks Research upgraded shares of Chemours (NYSE:CC) from a hold rating to a strong-buy rating in a report released on Tuesday morning,Zacks.com reports. Zacks Research also issued estimates for Chemours’ Q1 2027 earnings at $0.39 EPS, Q3 2027 earnings at $0.56 EPS, Q4 2027 earnings at $0.53 EPS, Q2 2028 earnings at $0.61 EPS and FY2028 earnings at $2.38 EPS.

A number of other research firms have also recently issued reports on CC. Mizuho cut their price objective on Chemours from $30.00 to $25.00 and set an “outperform” rating for the company in a research report on Wednesday, July 1st. UBS Group boosted their target price on Chemours from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Alembic Global Advisors restated an “overweight” rating and issued a $30.00 price target on shares of Chemours in a research note on Wednesday, May 13th. Truist Financial raised their price target on Chemours from $27.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Chemours from $17.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, May 21st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Chemours has a consensus rating of “Moderate Buy” and an average target price of $24.10.

Chemours Stock Down 4.0%

Chemours stock opened at $17.50 on Tuesday. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.82 and a quick ratio of 0.87. The company’s 50-day moving average is $20.47 and its 200-day moving average is $19.89. The firm has a market capitalization of $2.63 billion, a PE ratio of -6.63 and a beta of 1.41. Chemours has a fifty-two week low of $10.44 and a fifty-two week high of $28.67.

Chemours (NYSE:CC) last issued its earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.10. The business had revenue of $1.38 billion during the quarter, compared to the consensus estimate of $1.40 billion. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. Chemours’s revenue was up 1.0% on a year-over-year basis. During the same period last year, the business posted $0.13 EPS. Sell-side analysts anticipate that Chemours will post 1.18 earnings per share for the current year.

Chemours Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Sunday, May 17th were issued a $0.0875 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.35 dividend on an annualized basis and a yield of 2.0%. Chemours’s payout ratio is currently -13.26%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Atlas Capital Advisors Inc. acquired a new stake in shares of Chemours in the fourth quarter valued at approximately $26,000. Aster Capital Management DIFC Ltd acquired a new stake in Chemours during the fourth quarter worth approximately $28,000. Covestor Ltd increased its stake in Chemours by 204.7% during the 4th quarter. Covestor Ltd now owns 2,602 shares of the specialty chemicals company’s stock worth $31,000 after acquiring an additional 1,748 shares during the period. Eurizon Capital SGR S.p.A. bought a new position in Chemours during the 4th quarter worth $31,000. Finally, Rothschild Investment LLC raised its holdings in Chemours by 87.0% in the 4th quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company’s stock valued at $32,000 after acquiring an additional 1,255 shares in the last quarter. 76.26% of the stock is owned by institutional investors.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.